IL153405A0 - Method of treating cardiovascular disease with rapamycin - Google Patents
Method of treating cardiovascular disease with rapamycinInfo
- Publication number
- IL153405A0 IL153405A0 IL15340501A IL15340501A IL153405A0 IL 153405 A0 IL153405 A0 IL 153405A0 IL 15340501 A IL15340501 A IL 15340501A IL 15340501 A IL15340501 A IL 15340501A IL 153405 A0 IL153405 A0 IL 153405A0
- Authority
- IL
- Israel
- Prior art keywords
- rapamycin
- cardiovascular disease
- treating cardiovascular
- treating
- disease
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 229960002930 sirolimus Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21211700P | 2000-06-16 | 2000-06-16 | |
PCT/US2001/019179 WO2001097809A2 (en) | 2000-06-16 | 2001-06-14 | Method of treating cardiovascular disease using rapamycin |
Publications (1)
Publication Number | Publication Date |
---|---|
IL153405A0 true IL153405A0 (en) | 2003-07-06 |
Family
ID=22789625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15340501A IL153405A0 (en) | 2000-06-16 | 2001-06-14 | Method of treating cardiovascular disease with rapamycin |
Country Status (19)
Country | Link |
---|---|
US (1) | US20020013335A1 (xx) |
EP (1) | EP1292302A2 (xx) |
JP (1) | JP2003535899A (xx) |
KR (1) | KR20030010710A (xx) |
CN (1) | CN1436076A (xx) |
AR (1) | AR028959A1 (xx) |
AU (2) | AU2001268446B2 (xx) |
BR (1) | BR0111601A (xx) |
CA (1) | CA2412636A1 (xx) |
CZ (1) | CZ20024115A3 (xx) |
EA (1) | EA200300027A1 (xx) |
HU (1) | HUP0301244A3 (xx) |
IL (1) | IL153405A0 (xx) |
MX (1) | MXPA02012410A (xx) |
NO (1) | NO20026008D0 (xx) |
NZ (1) | NZ523114A (xx) |
PL (1) | PL365455A1 (xx) |
WO (1) | WO2001097809A2 (xx) |
ZA (1) | ZA200300418B (xx) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ307637B6 (cs) | 2001-02-19 | 2019-01-23 | Novartis Ag | 40-O-(2-Hydroxyethyl)rapamycin jako jediná účinná látka při léčení |
US20040137066A1 (en) * | 2001-11-26 | 2004-07-15 | Swaminathan Jayaraman | Rationally designed therapeutic intravascular implant coating |
US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
US20030176455A1 (en) * | 2002-03-13 | 2003-09-18 | Wyeth | Method of inhibiting cell death |
ATE385795T1 (de) | 2002-07-30 | 2008-03-15 | Wyeth Corp | Parenterale formulierungen mit einem rapamycin hydroxyester |
ATE413163T1 (de) * | 2002-09-17 | 2008-11-15 | Wyeth Corp | Granulierte formulierung des rapamycinesters ccl- 779 |
WO2004060283A2 (en) | 2002-12-16 | 2004-07-22 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
AR042938A1 (es) | 2003-02-06 | 2005-07-06 | Wyeth Corp | Uso del cci-779 en el tratamiento de la fibrosis hepatica |
US7728033B2 (en) | 2003-05-05 | 2010-06-01 | Clinigene International Private Limited | Mycophenolate mofetil in diabetic nephropathy |
US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
DE102004019845A1 (de) * | 2004-03-29 | 2005-10-20 | Krka Tovarna Zdravil D D | Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung |
US20050232965A1 (en) * | 2004-04-15 | 2005-10-20 | Robert Falotico | Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque |
EP1750862B1 (en) * | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
CN100435755C (zh) * | 2004-07-27 | 2008-11-26 | 微创医疗器械(上海)有限公司 | 药物洗脱支架 |
EP1656941A1 (en) * | 2004-11-09 | 2006-05-17 | Clinigene International Private Limited | Compositions for the treatment of diabetic nephropathy |
GB0503936D0 (en) | 2005-02-25 | 2005-04-06 | San Raffaele Centro Fond | Method |
CN100384416C (zh) * | 2006-03-20 | 2008-04-30 | 杨军 | 一种用于治疗心血管疾病的药物组合物 |
US20080175887A1 (en) * | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
WO2015103447A1 (en) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
EP2547642B1 (en) | 2010-03-15 | 2016-01-13 | ExxonMobil Chemical Patents Inc. | Processes for the production of alcohols |
WO2014059295A1 (en) * | 2012-10-12 | 2014-04-17 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
US10098871B2 (en) * | 2013-03-15 | 2018-10-16 | Leslie B. Gordon | Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
CN105997940A (zh) * | 2016-05-11 | 2016-10-12 | 中国人民解放军第三军医大学 | 炎症微环境响应性纳米药物、其制备方法及应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5373014A (en) * | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
GB9606452D0 (en) * | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
ATE283687T1 (de) * | 1997-06-13 | 2004-12-15 | Wyeth Corp | Rapamycin-formulierungen zur oralen verabreichung |
US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
-
2001
- 2001-06-13 US US09/880,295 patent/US20020013335A1/en not_active Abandoned
- 2001-06-14 JP JP2002503293A patent/JP2003535899A/ja active Pending
- 2001-06-14 AU AU2001268446A patent/AU2001268446B2/en not_active Ceased
- 2001-06-14 WO PCT/US2001/019179 patent/WO2001097809A2/en not_active Application Discontinuation
- 2001-06-14 CA CA002412636A patent/CA2412636A1/en not_active Abandoned
- 2001-06-14 BR BR0111601-0A patent/BR0111601A/pt not_active IP Right Cessation
- 2001-06-14 PL PL01365455A patent/PL365455A1/xx not_active Application Discontinuation
- 2001-06-14 EA EA200300027A patent/EA200300027A1/ru unknown
- 2001-06-14 NZ NZ523114A patent/NZ523114A/en unknown
- 2001-06-14 EP EP01946387A patent/EP1292302A2/en not_active Ceased
- 2001-06-14 HU HU0301244A patent/HUP0301244A3/hu unknown
- 2001-06-14 CZ CZ20024115A patent/CZ20024115A3/cs unknown
- 2001-06-14 IL IL15340501A patent/IL153405A0/xx unknown
- 2001-06-14 MX MXPA02012410A patent/MXPA02012410A/es not_active Application Discontinuation
- 2001-06-14 CN CN01811212A patent/CN1436076A/zh active Pending
- 2001-06-14 KR KR1020027017036A patent/KR20030010710A/ko not_active Application Discontinuation
- 2001-06-14 AU AU6844601A patent/AU6844601A/xx active Pending
- 2001-06-15 AR ARP010102877A patent/AR028959A1/es not_active Application Discontinuation
-
2002
- 2002-12-13 NO NO20026008A patent/NO20026008D0/no not_active Application Discontinuation
-
2003
- 2003-01-15 ZA ZA200300418A patent/ZA200300418B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP1292302A2 (en) | 2003-03-19 |
PL365455A1 (en) | 2005-01-10 |
AR028959A1 (es) | 2003-05-28 |
US20020013335A1 (en) | 2002-01-31 |
JP2003535899A (ja) | 2003-12-02 |
AU6844601A (en) | 2002-01-02 |
NO20026008L (no) | 2002-12-13 |
CN1436076A (zh) | 2003-08-13 |
ZA200300418B (en) | 2004-04-15 |
AU2001268446B2 (en) | 2005-08-11 |
MXPA02012410A (es) | 2003-04-25 |
HUP0301244A2 (hu) | 2003-08-28 |
WO2001097809A3 (en) | 2002-05-10 |
CA2412636A1 (en) | 2001-12-27 |
WO2001097809A2 (en) | 2001-12-27 |
CZ20024115A3 (cs) | 2003-06-18 |
BR0111601A (pt) | 2003-07-01 |
KR20030010710A (ko) | 2003-02-05 |
HUP0301244A3 (en) | 2005-01-28 |
EA200300027A1 (ru) | 2003-06-26 |
NZ523114A (en) | 2004-07-30 |
NO20026008D0 (no) | 2002-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL153405A0 (en) | Method of treating cardiovascular disease with rapamycin | |
GB0014969D0 (en) | Novel method of treatment | |
GB0008264D0 (en) | Novel method and compounds | |
HU0001471D0 (en) | New method of treatment | |
EP1443820A4 (en) | COMPOSITION AND METHOD FOR TREATING REACTION OF GRAFT AGAINST HOST | |
EP1176337A4 (en) | DAMPER AND METHOD FOR PRODUCING SAME | |
GB2366639B (en) | Method of comparing parts | |
GB0008921D0 (en) | Method of treatment | |
GB0026838D0 (en) | Treatment method | |
EP1267911A4 (en) | TREATMENT METHOD | |
PL341752A1 (en) | Method of obtaining aryloamino hydroxyantraquinones | |
IL161630A0 (en) | Methods of treating endometreosis | |
EP1303281A4 (en) | METHODS OF TREATMENT | |
GB0021481D0 (en) | Method of treating fabric | |
AU8626801A (en) | Method of forming complex | |
GB0002762D0 (en) | Method of treatment | |
PL333334A1 (en) | Method of obtaining silylethenes | |
GB0026742D0 (en) | Novel method of treatment | |
PL341488A1 (en) | Method of drying sludge | |
GB9929427D0 (en) | Method of knitting | |
PL339713A1 (en) | Method of obtaining triallylmethylamines | |
PL344809A1 (en) | Method of obtaining n-tert-butoxycarbonyl-l-ornitin | |
PL344651A1 (en) | Method of obtaining 4-demethoxydaunomycinone | |
PL344228A1 (en) | Method of obtaining paclitaxtel | |
GB0014904D0 (en) | Methods of treatment |